In this short video, Dr. Meteb Al Foheidi from the Department of Oncology at King Saud Bin Abdulaziz University for Health Science – NGHA, Jeddah, and the Chairman of Board of Directors of Saudi Oncology Society along with Dr. Mark Verrill from Northern Center for Cancer Care at Freeman Hospital, UK discuss the delay of chemotherapy in the HR+, HER2- MBC patients receiving Abemaciclib plus Fulvestrant.
